• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CRTX

CRTX

Cortexyme, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.95

+0.05 (+2.63%)

Company Profile

CEO

Casey Lynch

IPO Date

2019-05-09

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.91

Prev. Close

$1.90

Day Low

$1.86

Day High

$1.97

Market Cap

$0.07B

Volume

0.27M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

34.6%

Avg Negative

8.2%

Avg Neutral

57.3%

News Feed

Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case

Benzinga·8/16/2021·↑ positive

CRTX Stock Price Increased 47.32%: Why It Happened

Pulse2·8/9/2021·↑ positive

Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

Business Wire·7/23/2021·↑ positive

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

PRNewsWire·2/18/2021·↓ negative

Cortexyme: The OLE Study Hold Does Not Matter

Seeking Alpha·2/17/2021·↓ negative

Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease

Benzinga·2/16/2021·↑ positive

Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer's Disease

Business Wire·2/15/2021·↓ negative

Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion

Business Wire·2/10/2021·↑ positive

Cortexyme: A Fresh Perspective In Alzheimer's

Seeking Alpha·1/12/2021·↑ positive

Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?

Zacks Investment Research·1/6/2021·↑ positive